CL

Christoph Lengauer

Create the world’s best place to start a new therapeutics company

Boston, Massachusetts

Invests in

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Education

Work Experience

  • CSO & co-founder

    2022

    Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling dataset that enables an awesome Series A financing. And we do this at scale for 40+ companies / year.

  • Adjunct Associate Professor

    2005

  • Principal Investigator

    1994 - 2005

    Co-lead the molecular genetics lab together with Bert Vogelstein and Ken Kinzler. Was involved in the identification of several cancer driver genes incl. BRAF and PIK3CA. Discovered that all cancers are genetically unstable which explains the molecular heterogeneity of cancer and why cancers develop resistance to cancer drugs.

  • Consultant, R&D strategy

    2021 - 2022

    We envision a future where routine preventative care includes a blood test for cancer, just as patients are now routinely tested for early stages of heart disease. We know that if cancer is caught early, it often can be cured.

  • Chief Innovation Officer & co-founder

    2019 - 2021

  • CEO & founder

    2017 - 2022

    Advise Connect Inspire (ACI) helps European life sciences startups and emerging companies. We provide tailored support for young companies ranging from high-level strategic guidance to operational and tactical assistance. We are convinced that the complexity of building and growing a life sciences company calls for programs that are flexible and built around the needs of each company. We also understand the unique challenges of European companies that are trying to navigate a new ecosystem, and we know how to best help them.

  • Partner

    2018 - 2022

    Third Rock’s strategy is to discover, launch and build great companies - based on bold ideas that meet at the intersection of science, strategy, business and medicine. Blueprint - Relay - Celsius - Thrive - MOMA

  • Venture Partner

    2016 - 2018

  • Executive Vice President

    2016 - 2021

    Integrated Drug Development. Blueprint's singular focus is to use our deep understanding of the genetic blueprint of cancer and rare genetic diseases driven by the abnormal activation of kinases to craft highly selective medicines aimed at eradicating these diseases.

  • CSO

    2012 - 2016

    Chief Drug Hunter AYVAKIT (avapritinib) is a KIT/PDGFRA inhibitor approved for patients with advanced systemic mastocytosis (SM) and for patients with gastrointestinal stromal tumor (GIST), GAVRETO (pralsetinib) is a RET inhibitor approved for patients with RET+ non-small-cell lung carcinoma (NSCLC) and RET+ thyroid cancer.

2020 - 2021

  • CSO & co-founder

    2020 - 2021

    Molecular machines are enzymes that create force, work, and motion. We will discover the next generation of precision medicines by targeting the molecular machines that underlie human disease.

  • CSO, president & co-founder

    2018 - 2020

    How cells work together defines who we are, how we function and the diseases we have. Now, for the first time, we are able to see how individual cells interact at a level of resolution that was not previously possible.

  • Associate

    2018 - 2019

    The Creative Destruction Lab is a seed-stage program for massively scalable, science-based companies.

  • CEO

    2015 - 2019